Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Fred Middleton
AddedMar 31, 2024
UpdatedMay 31, 2026
Fred Middleton

Fred Middleton

Board Member, Chimerix

LinkedIn

Fred Middleton's Career

Chimerix
Chimerix

Durham, NC, US

Board Member· Board
Axikin Pharmaceuticals
Axikin Pharmaceuticals

San Diego, CA, US

Board Member· Board
Theravida
Theravida

Mountain View, CA, US

Board Member· Board
ViaCyte
ViaCyte

San Diego, CA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Fred Middleton's Career

Chimerix
Chimerix
Public$518.2M872000Durham, NC, US
Board Member· Board

Leadership at Chimerix

George PainterGeorge PainterFounder
Patrick HeronPatrick HeronBoard Member
Pratik MultaniPratik MultaniBoard Member
Martha J. DemskiMartha J. DemskiBoard Member
Michael AndrioleMichael AndrioleBoard Member
Patrick MachadoPatrick MachadoBoard Member

Similar to Chimerix

Antios TherapeuticsAntios TherapeuticsAtlanta, GA, USAntiviral Therapiesest. 2018Antios TherapeuticsAtlanta, GA, US · est. 2018

Antios Therapeutics: A global, clinical-stage biopharmaceutical company developing novel antiviral therapies.

Public · $200.4M35
ChimerosChimerosSan Diego, CA, USCancer Treatment, Medical Equipmentest. 2004ChimerosSan Diego, CA, US · est. 2004

ChimeraCore Inc.: A US-based provider of innovative cancer treatment solutions and medical equipment.

Pre-Seed · $3.6M6
Vir BiotechnologyVir BiotechnologySan Francisco, CA, USMedicines, Therapeuticsest. 2016Vir BiotechnologySan Francisco, CA, US · est. 2016

Vir Biotechnology, a clinical-stage firm, develops and commercializes treatments for viral and bacterial diseases in California.

Public · $908.6M576
Chromis TherapeuticsChromis TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2015Chromis TherapeuticsSan Diego, CA, US · est. 2015

San Diego-based Chromis Therapeutics, Inc. develops curative treatments for chronic HBV using advanced drug design.

Seed · $3M375
Axikin Pharmaceuticals
Axikin Pharmaceuticals
Public$18.5M302008San Diego, CA, US
Board Member· Board

Leadership at Axikin Pharmaceuticals

Walter OlesiakWalter OlesiakBoard Member
Kevin BaconKevin BaconBoard Member
Peter McWilliamsPeter McWilliamsBoard Member
Theravida
Theravida
Acquired$13.7M02005Mountain View, CA, US
Board Member· Board

Leadership at Theravida

Mehdi PaborjiMehdi PaborjiFounder
Ben McGrawBen McGrawBoard Member
George LasezkayGeorge LasezkayBoard Member
Nasser J KazeminyNasser J KazeminyBoard Member

Similar to Theravida

TherativeTherativeLivermore, CA, USSkincare DevicesTherativeLivermore, CA, US

Therative, Inc., a San Francisco-based company, develops and manufactures skincare devices and solutions for consumer use.

Series C · $14M5
Dignify TherapeuticsDignify TherapeuticsDurham, NC, USDrug Therapiesest. 2013Dignify TherapeuticsDurham, NC, US · est. 2013

Dignify Therapeutics, a US-based company, innovates drug therapies for bladder and bowel disorders.

Series A · $10.2M9
TherioTherioManhattan, KS, USPharmaceuticalsest. 2011TherioManhattan, KS, US · est. 2011

Therio, LLC, a Manhattan, Kansas-based pharmaceutical company established in 2011.

Seed · $275k5
TheraVascTheraVascCleveland, OH, USDrugs, Pharmaceuticalsest. 2009TheraVascCleveland, OH, US · est. 2009

TheraVasc Inc., a US pharmaceutical company, specializes in drugs for vascular diseases, particularly peripheral artery disease.

Public · $3.4M5
ViaCyte
ViaCyte
Public$235.5M1751999San Diego, CA, US
Board Member· Board

Leadership at ViaCyte

Carlos SchulerCarlos SchulerBoard Member
Paul LaikindPaul LaikindFounder
Michael YangMichael YangCEO

Similar to ViaCyte

CelularityCelularityFlorham Park, NJ, USCell Therapiesest. 2016CelularityFlorham Park, NJ, US · est. 2016

Celularity, a US-based biotech firm, pioneers in delivering large-scale, quality allogeneic placenta-derived cellular therapies.

Public · $400M225
Pathfinder Cell TherapyPathfinder Cell TherapyCambridge, MA, USCell Therapyest. 2007Pathfinder Cell TherapyCambridge, MA, US · est. 2007

Pathfinder Cell Therapy: Innovating cell-based treatments for organ-specific diseases and damage.

1
Cell Care TherapeuticsCell Care TherapeuticsMonrovia, CA, USBiopharmaceuticalsest. 2014Cell Care TherapeuticsMonrovia, CA, US · est. 2014

Cell Care Therapeutics: A California-based biopharmaceutical firm specializing in regenerative immunotherapies.

Seed · $5.3M7
SymbioCellTechSymbioCellTechSalt Lake City, UT, USCell Therapyest. 2006SymbioCellTechSalt Lake City, UT, US · est. 2006

SymbioCellTech: A biotech firm innovating cell therapy for long-term control of Type 1 Diabetes.

Series A · $15.5M8

Fred Middleton's Similar Executives & Operators

Jay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakLau Eng BoonLau Eng BoonBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoYun SeokYun SeokBoard Member · Kakao

People Similar to Fred Middleton

Tiffany OlsonTiffany OlsonBoard Member · Castle BiosciencesJames MaultJames MaultBoard Member · BoseBryan NolanBryan NolanCo-Founder · BiometryDon HardisonDon HardisonBoard Member · HTG Molecular DiagnosticsTerry WeberTerry WeberCEO · BioteJuan EnriquezJuan EnriquezFounder & CEO · Biotechonomy